Chemotherapy News and Research

Latest Chemotherapy News and Research

Diffusion Tensor Imaging MRI technique helps produce satisfactory images of nerve bundles

Standard MRI scans have so far been unable to produce satisfactory images of nerve bundles. However, this is now possible by an MRI technique called Diffusion Tensor Imaging (DTI). Matthan Caan succeeded in improving the DTI method during his PhD research at TU Delft, enabling him to produce more accurate images of the damage that radiotherapy and chemotherapy cause in young leukaemia patients.

15 Nov 2010

Exiqon publishes clinical study data on colon cancer

Exiqon A/S today published data from a clinical study that stratifies colon cancer patients into groups of high, medium and low chances of survival which may prove useful for optimizing the treatment of each individual cancer patient.

14 Nov 2010

Pro-Pharmaceuticals third quarter net loss decreases to $1,899,000

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for the third quarter and the nine months ended September 30, 2010. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the SEC.

12 Nov 2010

Researchers hope to prevent VTE complication in cancer patients

A major study is under way at The University of Nottingham which could lead to better prevention of a serious and sometimes fatal complication in cancer patients.

12 Nov 2010

Scientists unveil mechanism of liver regeneration

The liver's unique ability among organs to regenerate itself has been little understood. Now Weill Cornell Medical College scientists have shed light on how the liver restores itself by demonstrating that endothelial cells the cells that form the lining of blood vessels play a key role.

12 Nov 2010

COMP issues positive opinion for Celsion's ThermoDox Orphan Drug Designation

Celsion Corporation, a leading oncology drug development company, today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion on the application for Orphan Drug Designation for ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, for the treatment of hepatocellular carcinoma (HCC), commonly referred to as primary liver cancer.

12 Nov 2010

Study finds arsenic improves survival rate in APL patients

Arsenic, a toxic compound with a reputation as a good tool for committing homicide, has a significant positive effect on the survival of patients with acute promyelocytic leukemia (APL), when administered after standard initial treatment, according to a new, multi-center study led by a researcher at Wake Forest University Baptist Medical Center.

12 Nov 2010

NCI awards $11.5 million to Fred Hutchinson Center for breast cancer research

The National Cancer Institute has awarded $11.5 million to Fred Hutchinson Cancer Research Center to lead a five-year, Seattle-based breast cancer research consortium. The goal of the endeavor is to positively impact breast cancer prevention, detection, treatment and care of women who have or are at risk for the disease.

11 Nov 2010

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

NephRx Corporation today announced that it has initiated a Phase I clinical trial of its lead compound NX001 and has successfully dosed the first subject in the study. NX001, a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure, is in development for the prevention of delayed graft function (DGF) in kidney transplantation patients.

11 Nov 2010

News stories about cancer contain language that contribute to public uncertainty

New research from North Carolina State University shows that most online news stories about cancer contain language that likely contributes to public uncertainty about the disease a significant finding, given that at least one-third of Americans seek health information online.

11 Nov 2010

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today presented additional interim data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. The data were presented at the Chemotherapy Foundation Symposium being held in New York City.

11 Nov 2010

Dana-Farber lends iPads to cancer patients to help them pass the time in clinic

Andrea Casella comes to Dana-Farber Cancer Institute every week for chemotherapy to treat her lung cancer. It's a full day. Recognizing that patients can spend hours in the clinic for treatment and tests, Dana-Farber has started lending iPads to patients like Casella to help them pass the time.

11 Nov 2010

Aeterna Zentaris to present AEZS-108 Phase 2 results for endometrial cancer at EORTC-NCI-AACR Symposium

Aeterna Zentaris Inc. today announced that it will present a poster on Phase 2 results for AEZS-108 in advanced endometrial cancer at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held at the Berlin Estrel Hotel and Convention Centre in Berlin, Germany November 16 through 19, 2010.

11 Nov 2010

New discovery can develop diagnostic test to identify gene mutation in AML

Decoding the DNA of a woman who died of acute myeloid leukemia (AML) has led researchers at Washington University School of Medicine in St. Louis to a gene that they found to be commonly altered in many patients who died quickly of the disease.

11 Nov 2010

Nplate reduces treatment failure and splenectomies in adults with chronic immune thrombocytopenia

Amgen Inc. today announced the publication of results from the first open-label study to compare Nplate® (romiplostim) treatment to standard of care therapies (SOC) in non-splenectomized adult patients with chronic immune thrombocytopenia (ITP). The study results, which were published today in the New England Journal of Medicine (NEJM), show that both the incidence of treatment failure and need for splenectomy were reduced among the Nplate-treated patients.

11 Nov 2010

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that a compound identified by the Company as an antagonist of GPR87, an orphan GPCR recently unlocked for drug development by Omeros and linked to squamous cell carcinoma, potentiates the tumor-killing activity of doxorubicin (Adriamycin), a widely used chemotherapeutic agent.

10 Nov 2010

MonoSol Rx granted U.S. patent for PharmFilm and production technologies

MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in proprietary pharmaceutical film products, today announced that it has been granted U.S. patent No. 7,824,588 from the United States Patent and Trademark Office (USPTO). The patent, issued on November 2, 2010, provides intellectual property protection for the Company's film products and methods of their preparation.

10 Nov 2010

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, will be presented during the 22nd Annual Symposium of EORTC-NCI-AACR being held November 16-19, 2010 in Berlin, Germany.

10 Nov 2010

Medicinal mushroom formula fights breast cancer

Researchers at Indiana University and Methodist Research Institute studied an innovative medicinal mushroom formula against breast cancer. The impressive results are found in the December issue of the International Journal of Oncology. Lead investigator Dr. Daniel Sliva says, "The formula inhibits growth of highly metastatic human breast cancer cells, and suppresses metastatic potential of these cells."

10 Nov 2010

Senior Scientific receives QTDP grants for cancer detection and treatment

Manhattan Scientifics, Inc. (OTCBB: MHTX) announced that Senior Scientific LLC is the recipient of four grants totaling $702,899 awarded by the Qualifying Therapeutic Discovery Grant Program.

10 Nov 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Diffusion Tensor Imaging MRI technique helps produce satisfactory images of nerve bundles

Exiqon publishes clinical study data on colon cancer

Pro-Pharmaceuticals third quarter net loss decreases to $1,899,000

Researchers hope to prevent VTE complication in cancer patients

Scientists unveil mechanism of liver regeneration

COMP issues positive opinion for Celsion's ThermoDox Orphan Drug Designation

Study finds arsenic improves survival rate in APL patients

NCI awards $11.5 million to Fred Hutchinson Center for breast cancer research

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

News stories about cancer contain language that contribute to public uncertainty

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Dana-Farber lends iPads to cancer patients to help them pass the time in clinic

Aeterna Zentaris to present AEZS-108 Phase 2 results for endometrial cancer at EORTC-NCI-AACR Symposium

New discovery can develop diagnostic test to identify gene mutation in AML

Nplate reduces treatment failure and splenectomies in adults with chronic immune thrombocytopenia

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

MonoSol Rx granted U.S. patent for PharmFilm and production technologies

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

Medicinal mushroom formula fights breast cancer

Senior Scientific receives QTDP grants for cancer detection and treatment

Cancer Research - Second Edition eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Newsletters you may be interested in